HHGA
NTLA icon

Halbert Hargrove Global Advisors’s Intellia Therapeutics NTLA Stock Holding History

Halbert Hargrove Global Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-199
Closed -$3.44K – 621
2025
Q3 		$3.44K Buy
+199
New +$2.45K ﹤0.01% 474

Other funds holding NTLA

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Halbert Hargrove Global Advisors's NTLA Position: Q4 2025 in Review

Halbert Hargrove Global Advisors sold out of Intellia Therapeutics (NTLA) in Q4 2025, closing a stake of 199 shares — an estimated $3.44K sold.

Halbert Hargrove Global Advisors first reported a position in NTLA in Q3 2025 and held it in 1 quarter. The position peaked at $3.44K in Q3 2025. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

  • Halbert Hargrove Global Advisors reported no remaining Intellia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Halbert Hargrove Global Advisors sold 199 Intellia Therapeutics shares in Q4 2025, an estimated $3.44K.
  • Halbert Hargrove Global Advisors first reported a position in Intellia Therapeutics in Q3 2025 and held it in 1 quarter.
  • Halbert Hargrove Global Advisors's Intellia Therapeutics position peaked at $3.44K in Q3 2025.
  • 293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on Halbert Hargrove Global Advisors's 13F filing for Q4 2025, filed 23 Jan 2026.